Calvo-Cidoncha E, González-Bueno J, Almeida-González C V, Morillo-Verdugo R
Pharmacy Department, Valme University Hospital, Seville, Spain.
J Clin Pharm Ther. 2014 Apr;39(2):154-7. doi: 10.1111/jcpt.12120. Epub 2013 Dec 23.
Adherence to highly active antiretroviral treatment (HAART) is an important predictive factor of treatment outcome. Medication regimen complexity can be one of the main causes of non-adherence. Thus, treatment simplification is a key strategy in the development of antiretroviral therapy. The aim of this study was to determine the influence of adding etravirine on complexity index and patients' perceived complexity of their treatment regimen.
We conducted a prospective two-centre observational study. Patients on etravirine-based therapy, for at least 6 months, who came personally to pharmacy departments for a drug refill from February to July 2012 were included. Data were collected for the current etravirine-based HAART and for the previous HAART without etravirine. The main variables were complexity index and patients' perceived complexity. We also evaluated the adherence during the 6 months before and after the introduction of etravirine into HAART. The complexity index was based on a score which takes into account the number of pills per day, the dosing schedule, the dosage form and any specific instructions linked to use of the drug. To evaluate the patients' perceived complexity of their current and previous HAART, patients were asked to assign a mark on a visual analogue scale ranging from 0 (minimum) to 10 (maximum). We assessed the differences in the variables collected between the current and previous antiretroviral therapy. Finally, we carried out a correlation analysis between the complexity index and the patients' perceived complexity.
Eighty patients were included. The complexity index was significantly reduced after the addition of etravirine to HAART (P = 0·035). Perceived complexity was also reduced (P = 0·015). After the introduction of the drug, the proportion of adherent patients increased from 65% to 81·3% (P = 0·002). The correlation between the complexity index and the patients' perceived complexity was positive (r = 0·594). The correlation increased (r = 0·696) when the difference between the complexity index before and after the introduction of etravirine in HAART grew.
The addition of etravirine to HAART results in a significant reduction in complexity index and patients' perceived complexity of their therapy. These changes were associated with better adherence to treatment.
坚持高效抗逆转录病毒治疗(HAART)是治疗效果的重要预测因素。药物治疗方案的复杂性可能是导致不坚持治疗的主要原因之一。因此,简化治疗是抗逆转录病毒治疗发展的关键策略。本研究的目的是确定添加依曲韦林对复杂性指数以及患者对其治疗方案的感知复杂性的影响。
我们进行了一项前瞻性双中心观察性研究。纳入了2012年2月至7月亲自到药房部门 refill 药物且接受基于依曲韦林治疗至少6个月的患者。收集了当前基于依曲韦林的HAART以及之前不使用依曲韦林的HAART的数据。主要变量为复杂性指数和患者感知的复杂性。我们还评估了在HAART中引入依曲韦林前后6个月的依从性。复杂性指数基于一个分数,该分数考虑了每日服药片数、给药时间表、剂型以及与药物使用相关的任何特殊说明。为了评估患者对当前和之前HAART的感知复杂性,要求患者在0(最低)至10(最高)的视觉模拟量表上打分。我们评估了当前和之前抗逆转录病毒治疗之间收集的变量差异。最后,我们对复杂性指数和患者感知的复杂性进行了相关性分析。
纳入了80名患者。在HAART中添加依曲韦林后,复杂性指数显著降低(P = 0·035)。感知复杂性也降低了(P = 0·015)。引入该药物后,依从患者的比例从65%增加到81·3%(P = 0·002)。复杂性指数与患者感知的复杂性之间的相关性为正(r = 0·594)。当HAART中引入依曲韦林前后复杂性指数的差异增大时,相关性增加(r = 0·696)。
在HAART中添加依曲韦林可显著降低复杂性指数以及患者对其治疗的感知复杂性。这些变化与更好的治疗依从性相关。